1. Medtech Insight
  2. >>Policy & Regulation

Industry Says FDA Should Broaden Scope Of Pre-Submission Program

FDA should allow pre-submission meetings to occur earlier in a device’s development cycle than what is stated in the recent draft guidance, industry groups say. The agency should also agree to review prior data as part of these meetings.

FDA should expand the scope of device pre-submission meetings to allow for earlier interactions between the agency and companies, and broaden areas of discussion to include initial clinical data collected by firms, industry groups told FDA in comments on the recent pre-submission program draft guidance.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

FDA Reverses Course, Allows Some Telework For Reviewers

 
• By Derrick Gingery

The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.

Opportunity For Medtech To Contribute To EU Cybersecurity Recommendations

 
• By Amanda Maxwell

The deadline for comments is 30 June 2025

EU Harmonized Standards Continue To Trickle In Under MDR

 
• By Amanda Maxwell

Well over 200 European standards need harmonizing under the MDR. But only around 12% have been attended to so far.

Commission Needs To Prioritize Devices Agency Above All Else

 
• By Amanda Maxwell

Biomedical Alliance’s Tom Melvin is on a mission to assist the European Commission comprehend the clinical gaps during its ‘targeted evaluation’ of the EU's medtech regulations and the pivotal role the EMA could play.

More from Policy & Regulation